Demeclocycline
|
Systematic (IUPAC) name |
(2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-1,2,3,4,4a,5,5a,6,12,12a-decahydrotetracene-1,3,12-trione |
Clinical data |
Trade names |
Declomycin |
AHFS/Drugs.com |
monograph |
MedlinePlus |
a682103 |
Pregnancy cat. |
D (US) |
Legal status |
℞ Prescription only |
Routes |
Oral |
Pharmacokinetic data |
Bioavailability |
60–80% |
Protein binding |
41–50% |
Metabolism |
Hepatic |
Half-life |
10–17 hours |
Excretion |
Renal |
Identifiers |
CAS number |
127-33-3 Y
64-73-3 (HCl) |
ATC code |
D06AA01 J01AA01 |
PubChem |
CID 5311063 |
DrugBank |
DB00618 |
ChemSpider |
10482117 Y |
UNII |
5R5W9ICI6O Y |
KEGG |
D03680 Y |
ChEBI |
CHEBI:4392 Y |
ChEMBL |
CHEMBL1591 Y |
Chemical data |
Formula |
C21H21ClN2O8 |
Mol. mass |
464.853 g/mol |
SMILES
- CN(C)[C@@H]1C(\O)=C(\C(N)=O)C(=O)[C@@]2(O)C(/O)=C3/C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12
|
InChI
-
InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1 Y
Key:FMTDIUIBLCQGJB-SEYHBJAFSA-N Y
|
Y (what is this?) (verify)
|
Demeclocycline (marketed as Declomycin, Declostatin, and Ledermycin) is a tetracycline antibiotic derived from a strain of Streptomyces aureofaciens.[1]
Contents
- 1 Uses
- 2 Contraindications
- 3 Side effects and interactions
- 4 Mechanism of action
- 5 References
|
Uses
It is officially indicated for the treatment of various types of bacterial infections.[2] It is used as an antibiotic iin the treatment of Lyme disease, acne, and bronchitis.[citation needed] Resistance, though, is gradually becoming more common, and demeclocycline is now rarely used for infections.
It is widely used (though off-label in many countries) in the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) when fluid restriction alone has been ineffective.[3]
The use in SIADH actually relies on a side effect; demeclocycline induces nephrogenic diabetes insipidus (dehydration due to the inability to concentrate urine).[3] The use of demeclocycline in SIADH was first reported in 1975,[4] and, in 1978, a larger study found it to be more effective and better tolerated than lithium carbonate, the only available treatment at the time.[5] Demeclocycline has since been the drug of choice for treating SIADH, although it may be superseded as vasopressin receptor antagonists, such as tolvaptan, become available.[5]
Contraindications
Like other tetracyclines, demeclocycline is contraindicated in children and pregnant or nursing women. All members of this class interfere with bone development and may discolour teeth.[6]
Side effects and interactions
These are similar to those of other tetracyclines. Skin reactions with sunlight have been reported.[5] Demeclocycline is unique in that it is the only tetracycline known to cause nephrogenic diabetes insipidus.
Tetracyclines bind to cations, such as calcium, iron (when given orally), and magnesium, rendering them insoluble and inabsorbable for the gastrointestinal tract. Demeclocycline should not be taken with food (particularly milk and other dairy products) or antacids.[6]
Mechanism of action
As with related tetracycline antibiotics, demeclocycline acts by binding to the 30S and 50S ribosomal subunits, which impairs protein synthesis by bacteria. It is bacteriostatic (it impairs bacterial growth, but does not kill bacteria directly).
It is not completely understood why demeclocycline impairs the action of antidiuretic hormone, but is thought to block the binding of the hormone from its receptor.[7]
References
- ^ "demeclocycline" at Dorland's Medical Dictionary
- ^ "DailyMed: About DailyMed". http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=673. Retrieved 2008-12-20.
- ^ a b Goh KP (May 2004). "Management of hyponatremia". American Family Physician 69 (10): 2387–94. PMID 15168958. http://www.aafp.org/afp/20040515/2387.html.
- ^ Cherrill DA, Stote RM, Birge JR, Singer I (November 1975). "Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion". Annals of Internal Medicine 83 (5): 654–6. PMID 173218.
- ^ a b c Tolstoi LG (2002). "A brief review of drug-induced syndrome of inappropriate secretion of antidiuretic hormone". Medscape Pharmacotherapy 4 (1). http://www.medscape.com/viewarticle/420687_print. Retrieved on October 27, 2008.
- ^ a b Lexi-Comp (August 2008). "Demeclocycline". The Merck Manual Professional. http://www.merck.com/mmpe/lexicomp/demeclocycline.html. Retrieved on October 27, 2008.
- ^ De Troyer A, Demanet JC (1975). "Correction of antidiuresis by demeclocycline". N Engl J Med 293 (18): 915–8. doi:10.1056/NEJM197510302931809. PMID 170519.
Antibiotics and chemotherapeutics for dermatological use (D06)
|
|
Antibiotics |
Tetracycline and derivatives
|
- Demeclocycline
- Chlortetracycline
- Oxytetracycline
- Tetracycline
|
|
Others
|
- Amphenicol: Chloramphenicol
- Aminoglycosides: Neomycin
- Gentamicin
- Amikacin
- Streptogramin: Virginiamycin
- other: Fusidic acid
- Bacitracin
- Tyrothricin
- Mupirocin
|
|
|
Chemotherapeutics |
Sulfonamides
|
- Silver sulfadiazine
- Sulfathiazole
- Mafenide
- Sulfamethizole
- Sulfanilamide
- Sulfamerazine
|
|
Antivirals
|
- Aciclovir
- Penciclovir
- Idoxuridine
- Edoxudine
- Imiquimod/Resiquimod
- Podophyllotoxin
Docosanol
- Tromantadine
- Inosine
- Lysozyme
- Ibacitabine
|
|
Other
|
|
|
|
|
|
noco(i/b/d/q/u/r/p/m/k/v/f)/cong/tumr(n/e/d), sysi/epon
|
proc, drug (D2/3/4/5/8/11)
|
|
|
|
Antibacterials: protein synthesis inhibitors (J01A, J01B, J01F, J01G, QJ01XQ)
|
|
30S |
Aminoglycosides
(initiation inhibitors) |
-mycin (Streptomyces) |
- Streptomycin#
- Dihydrostreptomycin
- Neomycin#
- Framycetin
- Paromomycin
- Ribostamycin
- Kanamycin#
- Amikacin
- Arbekacin
- Bekanamycin
- Dibekacin
- Tobramycin
- Spectinomycin#
- Hygromycin B
|
|
-micin (Micromonospora) |
- Gentamicin#
- Netilmicin
- Sisomicin
- Isepamicin
|
|
|
Tetracycline antibiotics
(tRNA binding) |
Tetracyclines |
- Doxycycline#
- Chlortetracycline
- Clomocycline
- Demeclocycline
- Lymecycline
- Meclocycline
- Metacycline
- Minocycline
- Oxytetracycline
- Penimepicycline
- Rolitetracycline
- Tetracycline
|
|
Glycylcyclines |
|
|
|
|
50S |
Oxazolidinone
(initiation inhibitors) |
- Linezolid
- Torezolid
- Eperezolid
- Posizolid
- Radezolid
|
|
Peptidyl transferase |
Amphenicols |
- Chloramphenicol#
- Azidamfenicol
- Thiamphenicol
- Florfenicol
|
|
Pleuromutilins |
- Retapamulin
- Tiamulin
- Valnemulin
|
|
|
MLS (transpeptidation/translocation) |
Macrolides |
- Azithromycin#
- Clarithromycin
- Dirithromycin
- Erythromycin#
- Flurithromycin
- Josamycin
- Midecamycin
- Miocamycin
- Oleandomycin
- Rokitamycin
- Roxithromycin
- Spiramycin
- Troleandomycin
- Tylosin
- Ketolides
- Telithromycin
- Cethromycin
- Solithromycin
|
|
Lincosamides |
- Clindamycin#
- Lincomycin
- Pirlimycin
|
|
Streptogramins |
- Pristinamycin
- Quinupristin/dalfopristin
- Virginiamycin
|
|
|
|
EF-G |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
gr+f/gr+a(t)/gr-p(c)/gr-o
|
|
|
|
|
Antihypertensives: diuretics (C03)
|
|
Sulfonamides
(and etacrynic acid) |
CA inhibitors (at PT)
|
|
|
Loop (Na-K-Cl at AL)
|
- Furosemide#
- Bumetanide
- Etacrynic acid
- Etozoline
- Muzolimine
- Piretanide
- Tienilic acid
- Torasemide
|
|
Thiazides (Na-Cl at DCT,
Calcium-sparing)
|
- Hydrochlorothiazide#
- Bendroflumethiazide
- Hydroflumethiazide
- Chlorothiazide
- Polythiazide
- Trichlormethiazide
- Cyclopenthiazide
- Methyclothiazide
- Cyclothiazide
- Mebutizide
|
|
Thiazide-likes (primarily DCT)
|
- Quinethazone
- Clopamide
- Chlorthalidone
- Mefruside
- Clofenamide
- Metolazone
- Meticrane
- Xipamide
- Indapamide
- Clorexolone
- Fenquizone
|
|
|
Potassium-sparing (at CD) |
ESC blockers
|
- Amiloride#
- Triamterene
- Benzamil
|
|
Aldosterone antagonists
|
- Spironolactone#
- Eplerenone
- Potassium canrenoate
- Canrenone
|
|
|
Osmotic diuretics (PT, DL) |
|
|
Vasopressin receptor antagonists
(DCT and CD) |
- vaptans: Conivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
- tetracyclines: Demeclocycline
|
|
Other |
- mercurial diuretic (Mersalyl, Meralluride)
- Theobromine
- Cicletanine
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
anat(a:h/u/t/a/l,v:h/u/t/a/l)/phys/devp/cell/prot
|
noco/syva/cong/lyvd/tumr, sysi/epon, injr
|
proc, drug(C2s+n/3/4/5/7/8/9)
|
|
|
|
Neuropeptidergics
|
|
Cholecystokinin |
CCKA
|
- Agonists: Cholecystokinin
- CCK-4
Antagonists: Asperlicin
- Proglumide
- Lorglumide
- Devazepide
- Dexloxiglumide
|
|
CCKB
|
- Agonists: Cholecystokinin
- CCK-4
- Gastrin
Antagonists: Proglumide
- CI-988
|
|
|
CRH |
CRF1
|
- Agonists: Corticotropin releasing hormone
Antagonists: Antalarmin
- CP-154,526
- Pexacerfont
|
|
CRF2
|
- Agonists: Corticotropin releasing hormone
|
|
|
Galanin |
GAL1
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
GAL2
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
GAL3
|
- Agonists: Galanin
- Galmic
- Galnon
|
|
|
Ghrelin |
- Agonists: Ghrelin
- Capromorelin
- MK-677
- Sermorelin
- SM-130,686
- Tabimorelin
|
|
GnRH |
- Agonists: Buserelin
- Deslorelin
- GnRH
- Goserelin
- Histrelin
- Leuprorelin
- Nafarelin
- Triptorelin
Antagonists: Abarelix
- Cetrorelix
- Degarelix
- Ganirelix
|
|
MCH |
MCH1
|
- Agonists: Melanin concentrating hormone
Antagonists: ATC-0175
- GW-803,430
- NGD-4715
- SNAP-7941
- SNAP-94847
|
|
MCH2
|
- Agonists: Melanin concentrating hormone
|
|
|
Melanocortin |
MC1
|
- Agonists: alpha-MSH
- Afamelanotide
- BMS-470,539
- Bremelanotide
- Melanotan II
Antagonists: Agouti signalling peptide
|
|
MC2
|
- Agonists: ACTH
- Cosyntropin
- Tetracosactide
|
|
MC3
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
|
|
MC4
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
- PF-00446687
- THIQ
Antagonists: Agouti-related peptide
|
|
MC5
|
- Agonists: alpha-MSH
- Melanotan II
|
|
|
Neuropeptide S |
- Agonists: Neuropeptide S
Antagonists: SHA-68
|
|
Neuropeptide Y |
Y1
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIBP-3226
|
|
Y2
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIIE-0246
|
|
Y4
|
- Agonists: Neuropeptide Y
- Pancreatic polypeptide
- Peptide YY
Antagonists: UR-AK49
|
|
Y5
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: Lu AA-33810
|
|
|
Neurotensin |
NTS1
|
- Agonists: Neurotensin
- Neuromedin N
Antagonists: SR-48692
- SR-142,948
|
|
NTS2
|
- Agonists: Neurotensin
Antagonists: Levocabastine
- SR-142,948
|
|
|
Orexin |
OX1
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-334,867
- SB-408,124
- SB-649,868
- Suvorexant
|
|
OX2
|
- Agonists: Orexin-A
Antagonists: Almorexant
- SB-649,868
- Suvorexant
- TCS-OX2-29
|
|
|
Oxytocin |
- Agonists: Carbetocin
- Demoxytocin
- Oxytocin
- WAY-267,464
Antagonists: Atosiban
- Epelsiban
- L-371,257
- L-368,899
- Retosiban
|
|
Tachykinin |
NK1
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
NK2
|
- Agonists: Neurokinin A
Antagonists: GR-159,897
- Ibodutant
- Saredutant
|
|
NK3
|
- Agonists: Neurokinin B
Antagonists: Osanetant
- Talnetant
|
|
|
Vasopressin |
V1A
|
- Agonists: Desmopressin
- Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Relcovaptan
|
|
V1B
|
- Agonists: Felypressin
- Ornipressin
- Terlipressin
- Vasopressin
Antagonists: Demeclocycline
- Nelivaptan
|
|
V2
|
- Agonists: Desmopressin
- Ornipressin
- Vasopressin
Antagonists: Conivaptan
- Demeclocycline
- Lixivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
|
|
|